Satsuma Pharmaceuticals Valuation
| STSADelisted Stock | USD 1.10 0.01 0.90% |
Today, the company appears to be overvalued. Satsuma Pharmaceuticals has a current Real Value of $0.84 per share. The regular price of the company is $1.1. Our model measures the value of Satsuma Pharmaceuticals from inspecting the company fundamentals such as Shares Outstanding of 33.15 M, return on equity of -1.04, and Shares Owned By Institutions of 57.90 % as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Satsuma Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Satsuma Pharmaceuticals is based on 3 months time horizon. Increasing Satsuma Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Satsuma Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Satsuma Stock. However, Satsuma Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.1 | Real 0.84 | Hype 1.1 | Naive 1.21 |
The real value of Satsuma Stock, also known as its intrinsic value, is the underlying worth of Satsuma Pharmaceuticals Company, which is reflected in its stock price. It is based on Satsuma Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Satsuma Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Satsuma Pharmaceuticals helps investors to forecast how Satsuma stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Satsuma Pharmaceuticals more accurately as focusing exclusively on Satsuma Pharmaceuticals' fundamentals will not take into account other important factors: Satsuma Pharmaceuticals Total Value Analysis
Satsuma Pharmaceuticals is at this time projected to have valuation of (35.53 M) with market capitalization of 36.8 M, debt of 205 K, and cash on hands of 68.06 M. The negative valuation of Satsuma Pharmaceuticals may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Satsuma Pharmaceuticals fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(35.53 M) | 36.8 M | 205 K | 68.06 M |
Satsuma Pharmaceuticals Asset Utilization
One of the ways to look at asset utilization of Satsuma is to check how much profit was generated for every dollar of assets it reports. Satsuma Pharmaceuticals has a negative utilization of assets of -0.5 %, losing $0.004962 for each dollar of assets held by the company. Inadequate asset utilization indicates the company is being less effective with each dollar of assets it has. In other words, asset utilization of Satsuma Pharmaceuticals shows how discouraging it operates for each dollar spent on its assets.Satsuma Pharmaceuticals Ownership Allocation
Satsuma Pharmaceuticals shows a total of 33.15 Million outstanding shares. Over half of Satsuma Pharmaceuticals' outstanding shares are owned by institutional holders. These institutional holders are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Satsuma Pharmaceuticals Profitability Analysis
Net Loss for the year was (70.06 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Satsuma Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Satsuma Pharmaceuticals and how it compares across the competition.
About Satsuma Pharmaceuticals Valuation
The delisted stock valuation mechanism determines Satsuma Pharmaceuticals' current worth on a weekly basis. Our valuation model uses a comparative analysis of Satsuma Pharmaceuticals. We calculate exposure to Satsuma Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Satsuma Pharmaceuticals's related companies.Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. Satsuma Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 25 people.
Satsuma Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 32 M |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in Satsuma Stock
If you are still planning to invest in Satsuma Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Satsuma Pharmaceuticals' history and understand the potential risks before investing.
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |